• Mutation; HGNC; HGNC:9177; POLE; Simple; p.His67Asn (c.199C>A); ClinVar=VCV000473501; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission).
  
• Mutation; HGNC; HGNC:9177; POLE; Simple; p.Asp368Tyr; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission).
  
• Mutation; HGNC; HGNC:9177; POLE; Simple; p.Ala832Thr; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission).
  
• Mutation; HGNC; HGNC:9177; POLE; Simple; p.Cys1642Tyr; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission).
  
• Mutation; HGNC; HGNC:9177; POLE; Simple; p.Ala1967Val (c.5900C>T); ClinVar=VCV000246263; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission).
  
• Mutation; HGNC; HGNC:9177; POLE; Simple; p.Gly2076Val; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission).
  
• Mutation; HGNC; HGNC:9177; POLE; Simple; p.Leu2207Ile; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission).
  

PubMed=19920829; DOI=10.1038/sj.bjc.6605448; PMCID=PMC2813756
El-Sahwi K.S., Bellone S., Cocco E., Cargnelutti M., Casagrande F., Bellone M., Abu-Khalaf M., Buza N., Tavassoli F.A., Hui P., Silasi D.-A., Azodi M., Schwartz P.E., Rutherford T.J., Pecorelli S., Santin A.D.
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
Br. J. Cancer 102:134-143(2010)

PubMed=21246534; DOI=10.1002/cncr.25891; PMCID=PMC3128671
Varughese J., Cocco E., Bellone S., de Leon M., Bellone M., Todeschini P., Schwartz P.E., Rutherford T.J., Pecorelli S., Santin A.D.
Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.
Cancer 117:3163-3172(2011)

PubMed=23891627; DOI=10.1016/j.ajog.2013.07.020
English D.P., Bellone S., Cocco E., Bortolomai I., Pecorelli S., Lopez S., Silasi D.-A., Schwartz P.E., Rutherford T.J., Santin A.D.
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
Am. J. Obstet. Gynecol. 209:465.e1-465.e9(2013)

PubMed=27894751; DOI=10.1016/j.ygyno.2016.11.023; PMCID=PMC5183545
Bellone S., Bignotti E., Lonardi S., Ferrari F., Centritto F., Masserdotti A., Pettinella F., Black J.D., Menderes G., Altwerger G., Hui P., Lopez S., de Haydu C., Bonazzoli E., Predolini F., Zammataro L., Cocco E., Ferrari F., Ravaggi A., Romani C., Facchetti F., Sartori E., Odicino F.E., Silasi D.-A., Litkouhi B., Ratner E., Azodi M., Schwartz P.E., Santin A.D.
Polymerase epsilon (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
Gynecol. Oncol. 144:146-152(2017)